Brian Barash, MD
Psychiatry · Kansas City, MONPI 1689663049
Payments from drug & device makers
Across 1,560 payments — averaging $549.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$212K
- AbbVie$182K
- Supernus Pharmaceuticals, Inc.$123K
- Otsuka America Pharmaceutical, Inc.$109K
- Alkermes, Inc.$96K
- Axsome Therapeutics, Inc.$40K
- plus $96K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 240 | $211,985 |
| AbbVie(2 entities) | 408 | $181,723 |
| Supernus Pharmaceuticals, Inc. | 220 | $122,768 |
| Otsuka America Pharmaceutical, Inc. | 166 | $108,548 |
| Alkermes, Inc. | 116 | $96,147 |
| Axsome Therapeutics, Inc. | 38 | $39,525 |
| Tris Pharma Inc | 101 | $35,157 |
| Corium, LLC | 42 | $27,753 |
| Eisai Inc. | 32 | $15,665 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $14,580 |
| Sunovion Pharmaceuticals Inc. | 44 | $612 |
| Pfizer | 1 | $500 |
| Johnson & Johnson | 24 | $395 |
| Neos Therapeutics, LP | 19 | $280 |
| Vanda Pharmaceuticals Inc. | 16 | $207 |
| Lundbeck LLC | 19 | $203 |
| Shire North American Group Inc | 11 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $128 |
| Jazz Pharmaceuticals Inc. | 6 | $99 |
| Ironshore Pharmaceuticals Inc. | 5 | $88 |
| Vertical Pharmaceuticals, LLC | 5 | $72 |
| Brainsway USA Inc | 1 | $71 |
| Neuronetics, Inc. | 1 | $49 |
| Almatica Pharma LLC | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $10 |
How this compares
$856,807 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Kansas City
- Mark CannonKansas City$19K
- Syed KarimKansas City$17K
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.